Prostate Tissue Biobank for People at Genetic Risk for Aggressive Disease
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Clinical and pathological data for patients with prostate tissue samples
研究概览
简要总结
Prostate cancer is also the most common cancer in men with inherited pathogenic variants in BRCA1 and BRCA2. Beyond BRCA1/2, other genes are known to increase the risk of prostate cancer, including ATM, TP53 and HOXB13. The investigators have shown that 5% of men diagnosed with prostate cancer localized to their prostate gland and up to 10-15% of patients with metastatic prostate cancer gland are carriers of an inherited gene mutation.
The Prostate Tissue BioBank is a prospective study which aims to create a biorepository of prostate tissue samples from prostate biopsies and prostatectomies and matched germline DNA from pathogenic mutation carriers in addition to age-matched control samples. Our primary goal is to investigate prostate cancer development and treatment response in carriers of germline DNA repair mutations, as compared to non-carrier controls.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Carriers (Group 1):
- •Confirmed pathogenic or likely pathogenic variant in a known prostate cancer risk gene.
- •Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer
- •Controls (Group 2):
- •1. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer
排除标准
- 未提供
结局指标
主要结局
Clinical and pathological data for patients with prostate tissue samples
时间窗: 5 years
Data will be collected on consented patients who undergo prostate biopsy, prostatectomy or metastatic biopsy.
次要结局
未报告次要终点
研究者
Kara Maxwell
Principal investigator
Abramson Cancer Center at Penn Medicine